Downregulation of SERPINB13 expression in head and neck squamous cell carcinomas associates with poor clinical outcome

International Journal of Cancer

Volumn 125, Issue 7, 2009, Pages 1542-1550

  De Koning, Pieter J A ^a   Bovenschen, Niels ^a   Leusink, Frank K J ^a   Broekhuizen, Roel ^a   Quadir, Razi ^a   Van Gemert, Jan T M ^a   Hordijk, Gerrit J ^a   Chang, Wun Shaing W ^b   Van Der Tweel, Ingeborg ^a   Tilanus, Marcel G J ^c   Kummer, J Alain ^a,d  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

^c MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^d ST ANTONIUS HOSPITAL   (Netherlands)

Author keywords

HNSCC; SERPINB13; Tumor progression

Indexed keywords

MONOCLONAL ANTIBODY; SERINE PROTEINASE INHIBITOR; SERINE PROTEINASE INHIBITOR B13; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER PATIENT; CANCER SURVIVAL; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DOWN REGULATION; EMBRYO; EPITHELIUM CELL; FEMALE; HEAD AND NECK CARCINOMA; HETEROZYGOSITY LOSS; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MOUTH CARCINOMA; OROPHARYNX CARCINOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; SQUAMOUS CELL CARCINOMA; TUMOR DIFFERENTIATION;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, SQUAMOUS CELL; DOWN-REGULATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HEAD AND NECK NEOPLASMS; HUMANS; IMMUNOHISTOCHEMISTRY; LOSS OF HETEROZYGOSITY; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; MOUTH NEOPLASMS; NEOPLASM STAGING; OROPHARYNGEAL NEOPLASMS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROTEASE INHIBITORS; SERPINS; SKIN NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 68549097914     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.24507     Document Type: Article

References (41)

1. Chin D, Boyle GM, Porceddu S, Theile DR, Parsons PG, Coman WB. Head and neck cancer: past, present and future. Expert Rev Anticancer Ther 2006;6:1111-8.
2. Jones AS, Phillips DE, Helliwell TR, Roland NJ. Occult node metastases in head and neck squamous carcinoma. Eur Arch Otorhinolaryngol 1993;250:446-9.
3. Woolgar JA. Pathology of the N0 neck. Br J Oral Maxillofac Surg 1999;37:205-9.
4. Frank CJ, McClatchey KD, Devaney KO, Carey TE. Evidence that loss of chromosome 18q is associated with tumor progression. Cancer Res 1997;57:824-7.
5. Jones JW, Raval JR, Beals TF, Worsham MJ, Van Dyke DL, Esclamado RM, Wolf GT, Bradford CR, Miller T, Carey TE. Frequent loss of heterozygosity on chromosome arm 18q in squamous cell carcinomas. Identification of 2 regions of loss-18q11.1-q12.3 and 18q21.1-q23. Arch Otolaryngol Head Neck Surg 1997;123:610-4.
6. Pearlstein RP, Benninger MS, Carey TE, Zarbo RJ, Torres FX, Rybicki BA, Dyke DL. Loss of 18q predicts poor survival of patients with squamous cell carcinoma of the head and neck. Genes Chromosomes Cancer 1998;21:333-9.
7. Takebayashi S, Hickson A, Ogawa T, Jung KY, Mineta H, Ueda Y, Grenman R, Fisher SG, Carey TE. Loss of chromosome arm 18q with tumor progression in head and neck squamous cancer. Genes Chromosomes Cancer 2004;41:145-54.
8. Gettins PG. Serpin structure, mechanism, and function. Chem Rev 2002;102:4751-804.
9. Schneider SS, Schick C, Fish KE, Miller E, Pena JC, Treter SD, Hui SM, Silverman GA. A serine proteinase inhibitor locus at 18q21.3 contains a tandem duplication of the human squamous cell carcinoma antigen gene. Proc Natl Acad Sci USA 1995;92:3147-51.
10. Bartuski AJ, Kamachi Y, Schick C, Overhauser J, Silverman GA. Cytoplasmic antiproteinase 2 (PI8) and bomapin (PI10) map to the serpin cluster at 18q21.3. Genomics 1997;43:321-8.
11. Hasina R, Hulett K, Bicciato S, Di Bello C, Petruzzelli GJ, Lingen MW. Plasminogen activator inhibitor-2: a molecular biomarker for head and neck cancer progression. Cancer Res 2003;63:555-9.
12. Nakashima T, Yasumatsu R, Kuratomi Y, Masuda M, Kuwano T, Toh S, Umezaki T, Cataltepe S, Silverman GA, Komune S. Role of squamous cell carcinoma antigen 1 expression in the invasive potential of head and neck squamous cell carcinoma. Head Neck 2006;28:24-30.
13. Xia W, Lau YK, Hu MC, Li L, Johnston DA, Sheng S, El-Naggar A, Hung MC. High tumoral maspin expression is associated with improved survival of patients with oral squamous cell carcinoma. Oncogene 2000;19:2398-403.
14. Spring P, Nakashima T, Frederick M, Henderson Y, Clayman G. Identification and cDNA cloning of headpin, a novel differentially expressed serpin that maps to chromosome 18q. Biochem Biophys Res Commun 1999;264:299-304.
15. Abts HF, Welss T, Mirmohammadsadegh A, Kohrer K, Michel G, Ruzicka T. Cloning and characterization of hurpin (protease inhibitor 13): a new skin-specific. UV-repressible serine proteinase inhibitor of the ovalbumin serpin family. J Mol Biol 1999;293:29-39.
16. Gonzalez HE, Gujrati M, Frederick M, Henderson Y, Arumugam J, Spring PW, Mitsudo K, Kim HW, Clayman GL. Identification of 9 genes differentially expressed in head and neck squamous cell carcinoma. Arch Otolaryngol Head Neck Surg 2003;129:754-9.
17. Shellenberger TD, Mazumdar A, Henderson Y, Briggs K, Wang M, Chattopadhyay C, Jayakumar A, Frederick M, Clayman GL. Headpin: a serpin with endogenous and exogenous suppression of angiogenesis. Cancer Res 2005;65:11501-9.
18. Moussali H, Bylaite M, Welss T, Abts HF, Ruzicka T, Walz M. Expression of hurpin, a serine proteinase inhibitor, in normal and pathological skin: overexpression and redistribution in psoriasis and cutaneous carcinomas. Exp Dermatol 2005;14:420-8.
19. Bylaite M, Moussali H, Marciukaitiene I, Ruzicka T, Walz M. Expression of cathepsin L and its inhibitor hurpin in inflammatory and neoplastic skin diseases. Exp Dermatol 2006;15:110-8.
20. Kummer JA, Strik MC, Bladergroen BA, Hack CE. Production, characterization, and use of serpin antibodies. Methods 2004;32:141-9.
21. Bladergroen BA, Strik MC, Bovenschen N, van Berkum O, Scheffer GL, Meijer CJ, Hack CE, Kummer JA. The granzyme B inhibitor, protease inhibitor 9, is mainly expressed by dendritic cells and at immune-privileged sites. J Immunol 2001;166:3218-25.
22. Strik MC, Wolbink A, Wouters D, Bladergroen BA, Verlaan AR, van Houdt IS, Hijlkema S, Hack CE, Kummer JA. Intracellular serpin SERPINB6 (PI6) is abundantly expressed by human mast cells and forms complexes with beta-tryptase monomers. Blood 2004;103:2710-7.
23. Boukamp P, Petrussevska RT, Breitkreutz D, Hornung J, Markham A, Fusenig NE. Normal keratinization in a spontaneously immortalized aneuploid human keratinocyte cell line. J Cell Biol 1988;106:761-71.
24. Abts HF, Welss T, Scheuring S, Scott FL, Irving JA, Michel G, Bird PI, Ruzicka T. Sequence, organization, chromosomal localization, and alternative splicing of the human serine protease inhibitor gene hurpin (PI13) which is upregulated in psoriasis. DNA Cell Biol 2001;20:123-31.
25. Roepman P, Wessels LF, Kettelarij N, Kemmeren P, Miles AJ, Lijnzaad P, Tilanus MG, Koole R, Hordijk GJ, van der Vliet PC, Reinders MJ, Slootweg PJ, et al. An expression profile for diagnosis of lymph node metastases from primary head and neck squamous cell carcinomas. Nat Genet 2005;37:182-6.
26. Ramal LM, Feenstra M, van der Zwan AW, Collado A, Lopez-Nevot MA, Tilanus M, Garrido F. Criteria to define HLA haplotype loss in human solid tumors. Tissue Antigens 2000;55:443-8.
27. Wiernik G, Millard PR, Haybittle JL. The predictive value of histological classification into degrees of differentiation of squamous cell carcinoma of the larynx and hypopharynx compared with the survival of patients. Histopathology 1991;19:411-7.
28. Sano D, Myers JN. Metastasis of squamous cell carcinoma of the oral tongue. Cancer Metastasis Rev 2007;26:645-62.
29. Solomon E, Borrow J, Goddard AD. Chromosome aberrations and cancer. Science 1991;254:1153-60.
30. DeClerck YA, Mercurio AM, Stack MS, Chapman HA, Zutter MM, Muschel RJ, Raz A, Matrisian LM, Sloane BF, Noel A, Hendrix MJ, Coussens L, et al. Proteases, extracellular matrix, and cancer: a workshop of the path B study section. Am J Pathol 2004;164:1131-9.
31. Liotta LA, Tryggvason K, Garbisa S, Hart I, Foltz CM, Shafie S. Metastatic potential correlates with enzymatic degradation of basement membrane collagen. Nature 1980;284:67-8.
32. Mohamed MM, Sloane BF. Cysteine cathepsins: multifunctional enzymes in cancer. Nat Rev Cancer 2006;6:764-75.
33. Duffy MJ. Proteases as prognostic markers in cancer. Clin Cancer Res 1996;2:613-8.
34. Jayakumar A, Kang Y, Frederick MJ, Pak SC, Henderson Y, Holton PR, Mitsudo K, Silverman GA, AK EL-N, Bromme D, Clayman GL. Inhibition of the cysteine proteinases cathepsins K and L by the serpin headpin (SERPINB13): a kinetic analysis. Arch Biochem Biophys 2003;409:367-74.
35. Welss T, Sun J, Irving JA, Blum R, Smith AI, Whisstock JC, Pike RN, von Mikecz A, Ruzicka T, Bird PI, Abts HF. Hurpin is a selective inhibitor of lysosomal cathepsin L and protects keratinocytes from ultraviolet-induced apoptosis. Biochemistry 2003;42:7381-9.
36. Budihna M, Strojan P, Smid L, Skrk J, Vrhovec I, Zupevc A, Rudolf Z, Zargi M, Krasovec M, Svetic B, Kopitar-Jerala N, Kos J. Prognostic value of cathepsins B. H, L, D and their endogenous inhibitors stefins. A and. B in head and neck carcinoma. Biol Chem Hoppe Seyler 1996;377:385-90.
37. Troy AM, Sheahan K, Mulcahy HE, Duffy MJ, Hyland JM, O'Donoghue DP. Expression of Cathepsin B and L antigen and activity is associated with early colorectal cancer progression. Eur J Cancer 2004;40:1610-6.
38. Jagodic M, Vrhovec I, Borstnar S, Cufer T. Prognostic and predictive value of cathepsins D and L in operable breast cancer patients. Neoplasma 2005;52:1-9.
39. Kleer CG, Bloushtain-Qimron N, Chen YH, Carrasco D, Hu M, Yao J, Kraeft SK, Collins LC, Sabel MS, Argani P, Gelman R, Schnitt SJ, et al. Epithelial and stromal cathepsin K and CXCL14 expression in breast tumor progression. Clin Cancer Res 2008;14:5357-67.
40. Quintanilla-Dieck MJ, Codriansky K, Keady M, Bhawan J, Runger TM. Cathepsin K in melanoma invasion. J Invest Dermatol 2008;128:2281-8.
41. Zhang M, Volpert O, Shi YH, Bouck N. Maspin is an angiogenesis inhibitor. Nat Med 2000;6:196-9.